Clonal Hematopoiesis and Cardiovascular Risk | JACC | ESC 2025

In this JACC interview, Michael Honigberg, MD, MPP joins Mitsuaki Sawano, MD, PhD, to discuss two simultaneous publications presented at ESC 2025 on the role of clonal hematopoiesis of indeterminate potential (CHIP) in cardiovascular disease. They highlight findings from the Women’s Health Initiative Long Life Study, which examined CHIP in older women and revealed gene-specific risks (TET2, JAK2, ASXL1) linked to heart failure, coronary heart disease, and thromboembolism. They also review results from the LoDoCo2 trial substudy, showing how colchicine may blunt CHIP clonal growth—particularly TET2 mutations—and reduce IL-6 inflammation, suggesting new avenues for targeted prevention. The discussion concludes with a forward-looking perspective on the future of CHIP research, its therapeutic implications, and its potential to transform cardiovascular clinical practice.